Clinical Trial Update: Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of Milsaperidone as adjunctive therapy for Major Depressive Disorder; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Milsaperidone (Milsaperidone)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Major Depressive Disorder (MDD) | Phase 3 | Status: RECRUITING